MEDITERA TIBBI MALZEMEMM

MEDITERA TIBBI MALZEME

44.94TRYD
−0.04−0.09%
At close at 15:05 GMT
TRY
No trades
See on Supercharts

MEDTR fundamentals

MEDITERA TIBBI MALZEME financial statements, including revenue, expenses, and profit

The total revenue of MEDTR for the last quarter is 553.05 M TRY, and it's 49.44% higher compared to the previous quarter. The net income of Q3 24 is 18.39 M TRY.

Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−250.00 M‬‬
‪0.00‬
‪‪250.00 M‬‬
‪‪500.00 M‬‬
‪‪750.00 M‬‬
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: TRY
Q2 '21
Jun 2021
Q3 '21
Sep 2021
Q4 '21
Dec 2021
Q1 '22
Mar 2022
Q2 '22
Jun 2022
Q3 '22
Sep 2022
Q4 '22
Dec 2022
Q2 '23
Jun 2023
Q3 '23
Sep 2023
Q4 '23
Dec 2023
Q1 '24
Mar 2024
Q2 '24
Jun 2024
Q3 '24
Sep 2024
TTM
Total revenueYoY growth
‪‪218.82 M‬‬
+131.76%
‪‪205.85 M‬‬
+57.44%
‪‪272.10 M‬‬
+62.01%
‪‪343.23 M‬‬
+60.83%
‪‪611.91 M‬‬
+179.64%
‪‪435.53 M‬‬
+111.57%
‪‪370.09 M‬‬
+36.01%
‪‪553.05 M‬‬
+61.13%
‪‪1.97 B‬‬
‪‪−126.18 M‬‬
‪‪−119.80 M‬‬
‪‪−152.48 M‬‬
‪‪−167.26 M‬‬
‪‪−392.32 M‬‬
‪‪−257.92 M‬‬
‪‪−218.98 M‬‬
‪‪−344.29 M‬‬
‪‪−1.21 B‬‬
Gross profitYoY growth
‪‪92.64 M‬‬
+145.82%
‪‪86.05 M‬‬
+38.41%
‪‪119.62 M‬‬
+46.93%
‪‪175.97 M‬‬
+67.46%
‪‪219.59 M‬‬
+137.02%
‪‪177.60 M‬‬
+106.40%
‪‪151.11 M‬‬
+26.32%
‪‪208.76 M‬‬
+18.64%
‪‪757.07 M‬‬
‪‪−34.84 M‬‬
‪‪−39.93 M‬‬
‪‪−62.79 M‬‬
‪‪−73.53 M‬‬
‪‪−154.68 M‬‬
‪‪−104.69 M‬‬
‪‪−94.81 M‬‬
‪‪−120.00 M‬‬
‪‪−474.18 M‬‬
‪‪57.80 M‬‬
+170.49%
‪‪46.12 M‬‬
+21.84%
‪‪56.83 M‬‬
−1.92%
‪‪102.44 M‬‬
+46.20%
‪‪64.90 M‬‬
+12.28%
‪‪72.91 M‬‬
+58.10%
‪‪56.30 M‬‬
−0.94%
‪‪88.76 M‬‬
−13.35%
‪‪282.88 M‬‬
‪‪29.77 M‬‬
‪‪15.72 M‬‬
‪‪53.84 M‬‬
‪‪47.05 M‬‬
‪‪−314.33 M‬‬
‪‪−9.81 M‬‬
‪‪−91.02 M‬‬
‪‪−40.90 M‬‬
‪‪−465.53 M‬‬
Pretax incomeYoY growth
‪‪87.58 M‬‬
+266.96%
‪‪61.85 M‬‬
−56.96%
‪‪110.68 M‬‬
+25.97%
‪‪149.49 M‬‬
+54.61%
‪‪−249.43 M‬‬
−384.81%
‪‪63.11 M‬‬
+2.04%
‪‪−34.72 M‬‬
−131.37%
‪‪47.87 M‬‬
−67.98%
‪‪−173.17 M‬‬
‪‪−427.48 K‬‬
‪‪−546.43 K‬‬
‪‪−1.30 M‬‬
‪‪−1.14 M‬‬
‪‪−4.15 M‬‬
‪‪−746.30 K‬‬
‪‪−1.06 M‬‬
‪‪−5.15 M‬‬
‪‪−11.11 M‬‬
‪‪−13.73 M‬‬
‪‪−2.05 M‬‬
‪‪−10.58 M‬‬
‪‪−28.30 M‬‬
‪‪8.83 M‬‬
‪‪−51.76 M‬‬
‪‪62.36 M‬‬
‪‪−24.45 M‬‬
‪‪−5.02 M‬‬
‪0.00‬
‪‪28.82 K‬‬
‪‪21.89 K‬‬
‪‪188.33 K‬‬
‪‪−313.25 K‬‬
‪‪2.95 K‬‬
‪‪492.70 K‬‬
‪‪126.43 K‬‬
‪‪308.84 K‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪73.41 M‬‬
‪‪59.28 M‬‬
‪‪98.82 M‬‬
‪‪120.24 M‬‬
‪‪−245.05 M‬‬
‪‪10.60 M‬‬
‪‪27.07 M‬‬
‪‪18.39 M‬‬
‪‪−188.99 M‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
Net incomeYoY growth
‪‪73.41 M‬‬
+299.01%
‪‪59.28 M‬‬
−51.25%
‪‪98.82 M‬‬
+41.14%
‪‪120.24 M‬‬
+27.47%
‪‪−245.05 M‬‬
−433.80%
‪‪10.60 M‬‬
−82.11%
‪‪27.07 M‬‬
−72.60%
‪‪18.39 M‬‬
−84.71%
‪‪−188.99 M‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪73.41 M‬‬
‪‪59.28 M‬‬
‪‪98.82 M‬‬
‪‪120.24 M‬‬
‪‪−245.05 M‬‬
‪‪10.60 M‬‬
‪‪27.07 M‬‬
‪‪18.39 M‬‬
‪‪−188.99 M‬‬
‪0.62‬
+299.03%
‪0.50‬
−51.25%
‪0.83‬
+41.15%
‪1.01‬
+27.46%
‪−2.06‬
−433.81%
‪0.09‬
−82.12%
‪0.23‬
−72.61%
‪0.15‬
−84.71%
‪−1.59‬
‪0.62‬
+299.03%
‪0.50‬
−51.25%
‪0.83‬
+41.15%
‪1.01‬
+27.46%
‪−2.06‬
−433.81%
‪0.09‬
−82.12%
‪0.23‬
−72.61%
‪0.15‬
−84.71%
‪−1.59‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
‪‪119.00 M‬‬
EBITDAYoY growth
‪‪60.77 M‬‬
+151.81%
‪‪49.28 M‬‬
+21.65%
‪‪60.42 M‬‬
−0.27%
‪‪106.43 M‬‬
+46.00%
‪‪106.35 M‬‬
+75.00%
‪‪88.70 M‬‬
+79.98%
‪‪73.47 M‬‬
+21.61%
‪‪108.14 M‬‬
+1.61%
‪‪376.67 M‬‬
EBITYoY growth
‪‪57.80 M‬‬
+170.49%
‪‪46.12 M‬‬
+21.84%
‪‪56.83 M‬‬
−1.92%
‪‪102.44 M‬‬
+46.20%
‪‪64.90 M‬‬
+12.28%
‪‪72.91 M‬‬
+58.10%
‪‪56.30 M‬‬
−0.94%
‪‪88.76 M‬‬
−13.35%
‪‪282.88 M‬‬
‪‪−161.02 M‬‬
‪‪−159.73 M‬‬
‪‪−215.27 M‬‬
‪‪−240.79 M‬‬
‪‪−547.01 M‬‬
‪‪−362.61 M‬‬
‪‪−313.79 M‬‬
‪‪−464.29 M‬‬
‪‪−1.69 B‬‬